Other: inhaled hyperpolarized xenon-129 (DrugBank: Xenon)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
228 | Bronchiolitis obliterans | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04029636 (ClinicalTrials.gov) | August 2019 | 7/6/2019 | Hyperpolarized 129Xe MRI for the Assessment of BOS With Late Onset LONIPC | Hyperpolarized 129Xe Magnetic Resonance Imaging for the Early Detection of Bronchiolitis Obliterans Syndrome (BOS) and Other Late Onset Non-infectious Pulmonary Complications (LONIPCs) Following Hematopoietic Stem Cell Transplantation | Bronchiolitis Obliterans | Other: Inhaled Hyperpolarized Xenon-129 | Hamilton Health Sciences Corporation | NULL | Not yet recruiting | 18 Years | 70 Years | All | 45 | Canada |